Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning

Clinical Ophthalmology
Noriko MiyamotoYasuo Kurimoto

Abstract

To evaluate the response to and dependence on aflibercept or ranibizumab in patients with age-related macular degeneration (AMD). We retrospectively reviewed AMD patients who received induction therapy with aflibercept or ranibizumab for the following parameters: whether complete resolution of the retinal fluid ("good response") was achieved and whether recurrence was observed within 3 months ("dependent") after the induction treatment. With aflibercept treatment, treatment-naïve eyes with a good response/non-dependence were recommended a pro re nata regimen, and other eyes were recommended a proactive bimonthly regimen, followed by monitoring of visual acuity (VA) for 12 months. The measured values of the groups were compared using one-way analysis of variance with Tukey's test to evaluate the difference between baseline and postinjection VA. Among the treatment-naïve eyes, 76% had a good response to aflibercept and 37% of these were aflibercept-dependent, while 58% had a good response to ranibizumab but 51% of these were ranibizumab-dependent. Among the eyes that converted from ranibizumab treatment, 92% of the good responders to ranibizumab with dependence and 76% of the poor responders on ranibizumab had a good response to ...Continue Reading

Citations

Aug 6, 2018·The British Journal of Ophthalmology·Noriko MiyamotoYasuo Kurimoto
Jun 1, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Siva P KambhampatiRangaramanujam M Kannan
Jul 13, 2021·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Sean D AdreanScott Grant

❮ Previous
Next ❯

Software Mentioned

PrONTO
MARINA
SPSS

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.